These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 34488897)

  • 1. Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality.
    Fernando ME; Drovandi A; Golledge J
    Syst Rev; 2021 Sep; 10(1):243. PubMed ID: 34488897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.
    Kumar S; Nikravesh M; Chukwuemeka U; Randazzo M; Flores P; Choday P; Raja A; Aseri M; Shivang S; Chaudhuri S; Barve P
    Clin Cardiol; 2022 Jul; 45(7):759-766. PubMed ID: 35481554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
    Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
    Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis.
    Lo KB; Bhargav R; Salacup G; Pelayo J; Albano J; McCullough PA; Rangaswami J
    Expert Rev Cardiovasc Ther; 2020 Dec; 18(12):919-930. PubMed ID: 32945216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis.
    Zhang X; Yu J; Pan LY; Jiang HY
    Pharmacol Res; 2020 Aug; 158():104927. PubMed ID: 32422341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
    Oussalah A; Gleye S; Clerc Urmes I; Laugel E; Callet J; Barbé F; Orlowski S; Malaplate C; Aimone-Gastin I; Caillierez BM; Merten M; Jeannesson E; Kormann R; Olivier JL; Rodriguez-Guéant RM; Namour F; Bevilacqua S; Losser MR; Levy B; Kimmoun A; Gibot S; Thilly N; Frimat L; Schvoerer E; Guéant JL
    Clin Infect Dis; 2020 Dec; 71(9):2447-2456. PubMed ID: 32623470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
    Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
    PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies.
    Bavishi C; Whelton PK; Mancia G; Corrao G; Messerli FH
    J Hypertens; 2021 Apr; 39(4):784-794. PubMed ID: 33560054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Grover A; Oberoi M
    Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
    PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
    Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA
    Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
    Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.
    Huang NX; Yuan Q; Fang F; Yan BP; Sanderson JE
    PLoS One; 2023; 18(1):e0280280. PubMed ID: 36634085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACEi/ ARB and Deaths of COVID-19 Patients.
    Azad GN; Kumar A
    Curr Hypertens Rev; 2022; 18(2):158-162. PubMed ID: 35392786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.